Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Journal of Hepatology|July 30, 2023
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitisArun J Sanyal, Vlad Ratziu, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|July 2, 2013
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinaseTakuji Ishimoto, Miguel A Lanaspa, Christopher J Rivard, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2024
Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASHJason D Coombes, Paul P Manka, Marzena Swiderska-Syn, et al.
Hepatology (Baltimore, Md.)|October 23, 2010
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitisWing-Kin Syn, Steve S Choi, Evaggelia Liaskou, et al.
JHEP Reports : Innovation in Hepatology|June 9, 2025
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatmentPierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisZobair M Younossi, Rohit Loomba, Mary E Rinella, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Hepatology (Baltimore, Md.)|December 10, 2017
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisZobair M Younossi, Rohit Loomba, Quentin M Anstee, et al.
Pageof 16